JDDW2022 (Japan Digestive Disease Week 2022) FUKUOKA

Chairperson's Comment

International Session
(Symposium) 2

October 28th  14:30–17:00  Room8

Call for Papers

From basic to clinical research: The strategy for new treatments for liver fibrosis and cirrhosis
Chairperson Hitoshi Yoshiji Department of Gastroenterology, Nara Medical University
Shuji Terai Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University
Liver cirrhosis is progressive disease. Now we can treat HBV and HCV related liver cirrhosis, but the therapy to cure liver fibrosis itself is still unmet demand. Basic study to understand the mechanism of liver fibrosis is proceeding. Concerning with evaluation method to analyze liver fibrosis (biomarker and elastography) were also progressed in clinical field. On the other hands, new strategy using drug, cell, gene and exosome is developing. To develop a next generation therapy for liver cirrhosis in clinical, adequate design of clinical study and trial is needed. In this symposium we will discuss the current status of diagnosis and therapy for liver cirrhosis and new findings of liver cirrhosis therapy and sum up the strategy of next step.

Back to top